A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice
Crossref DOI link: https://doi.org/10.1186/s13550-015-0088-0
Published Online: 2015-03-20
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Slobbe, Paul
Windhorst, Albert D
Stigter-van Walsum, Marijke
Smit, Egbert F
Niessen, Heiko G
Solca, Flavio
Stehle, Gerd
van Dongen, Guus A M S
Poot, Alex J
License valid from 2015-03-20